Last reviewed · How we verify

NCT05239884

CSD201202: A Study to Assess Nicotine Uptake From Electronic Nicotine Delivery System P12

Completed NA Last updated 24 June 2022
What this trial tests

NA trial testing ENDS Product A with 1.5% nicotine in Smoking in 36 participants. Completed in 15 April 2022.

Timeline
14 March 2022
Primary endpoint
15 April 2022
15 April 2022

Quick facts

Lead sponsorRAI Services Company
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposeother
Enrollment36
Start date14 March 2022
Primary completion15 April 2022
Estimated completion15 April 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

RAI Services Company

Who can join

Adults 21 to 60, any sex, with Smoking or Tobacco Use. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, randomized, 8-way crossover study designed to evaluate plasma nicotine pharmacokinetic (PK) parameters following an ad libitum use of Electronic Nicotine Delivery System (ENDS) investigational products (IPs) in a confinement setting by generally healthy combustible cigarette (CC) smokers and dual users of CC and ENDS.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Smoking

Currently open trials in the same condition.

Other RAI Services Company trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05239884.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing